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The gut microbiota: a major player in the toxicity
of environmental pollutants?
Sandrine P Claus1, Hervé Guillou2 and Sandrine Ellero-Simatos2
Exposure to environmental chemicals has been linked to various health disorders, including obesity, type 2 diabetes, cancer and
dysregulation of the immune and reproductive systems, whereas the gastrointestinal microbiota critically contributes to a variety of
host metabolic and immune functions. We aimed to evaluate the bidirectional relationship between gut bacteria and
environmental pollutants and to assess the toxicological relevance of the bacteria–xenobiotic interplay for the host. We examined
studies using isolated bacteria, faecal or caecal suspensions—germ-free or antibiotic-treated animals—as well as animals
reassociated with a microbiota exposed to environmental chemicals. The literature indicates that gut microbes have an extensive
capacity to metabolise environmental chemicals that can be classiﬁed in ﬁve core enzymatic families (azoreductases,
nitroreductases, β-glucuronidases, sulfatases and β-lyases) unequivocally involved in the metabolism of 430 environmental
contaminants. There is clear evidence that bacteria-dependent metabolism of pollutants modulates the toxicity for the host.
Conversely, environmental contaminants from various chemical families have been shown to alter the composition and/or the
metabolic activity of the gastrointestinal bacteria, which may be an important factor contributing to shape an individual’s
microbiotype. The physiological consequences of these alterations have not been studied in details but pollutant-induced
alterations of the gut bacteria are likely to contribute to their toxicity. In conclusion, there is a body of evidence suggesting that gut
microbiota are a major, yet underestimated element that must be considered to fully evaluate the toxicity of environmental
contaminants.
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INTRODUCTION
The human gut microbiota is a dynamic ecosystem formed by a
pool of 400–1000 adherent and non-adherent bacterial species
belonging mostly to two dominant phyla, the Firmicutes and the
Bacteroidetes.1 Although the composition of an adult microbiota
remains relatively stable, it is well known that the microbial
diversity is acquired very early in life within the ﬁrst hours post
birth, and is shaped over time as the diet becomes more complex
and the immune-system matures. Hence, the combination of
multiple factors including genotype, mode of delivery, early
antibiotic therapy, diet composition, lifestyle, social interactions
and environmental exposure to various xenobiotics shape the gut
microbiota to make every individual microbially unique.2,3 This is
of importance because the gut microbiota fulﬁlls many critical
roles in essential host functions such as protection against
pathogens, immune-system modulation, fermentation of non-
digestible dietary ﬁbres, anaerobic metabolism of peptides and
proteins, interaction with the host’s circadian clock and biotrans-
formation of xenobiotics.4–6 Such a complex symbiotic interaction
is the result of a remarkable metabolic activity driven by a genetic
pool whose size is a hundred times larger than the human one.
Alterations of the microbiota composition (called dysbiosis) and/or
optimal functions are associated with various prevalent metabolic
and immune diseases, including obesity,7 inﬂammatory bowel
disease,8 diabetes,9 hepatic diseases,10,11 Crohn’s disease,12
colorectal cancer13 and allergy.14
Synthetic chemicals currently used for diverse industrial and
agricultural applications are leading to widespread contamination
of the environment and their effects on human health are a global
concern. Mounting evidence indicates that exposure to these
environmental chemicals is one of the multiple environmental
factors contributing to the development of several health
disorders. In vitro, in vivo and epidemiological studies have,
for example, linked human exposure to endocrine-disrupting
chemicals to obesity, metabolic syndrome and type 2 diabetes.15
However, it is unclear how the gastrointestinal (GI) microbiota and
environmental chemicals interact and whether these interactions
are relevant for human health. In a recent review, it was suggested
that GI microbes might affect obesity and diabetes by altering the
absorption, disposition, metabolism and excretion of environ-
mental chemicals.16 Here we aimed to describe how environ-
mental chemicals and GI microorganisms might interact and to
evaluate the toxicological relevance of these interactions. We
identiﬁed four different types of interactions, illustrated in
Figure 1: ﬁrst, the GI microbiota can metabolise a variety of
environmental chemicals, directly upon ingestion (Figure 1a) or
after their conjugation by the liver (Figure 1b). Reciprocally,
environmental chemicals can interfere with the composition
(Figure 1c) and/or metabolic activity (Figure 1d) of the GI
microbiota, with potentially deleterious consequences for the
host. Table 1 presents information on the levels of exposure of the
various compounds that are presented in this review and brieﬂy
summarises their interaction with the gut microbiota.
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THE GI MICROBIOTA CAN METABOLISE ENVIRONMENTAL
CHEMICALS
GI microorganisms have been known for decades to be involved
in the biotransformation of xenobiotics. Back in 1973, Scheline
suggested that the potential of the GI microbiota to metabolise
foreign compounds was at least as great as that of the liver.17
More than 40 drug substrates have since been identiﬁed for the
GI microbiota,5,18–21 highlighting the ability of gut microbes to
perform diverse chemical transformations on drugs, including
reduction, hydrolysis, the removal of a succinate group,
dehydroxylation, acetylation, deacetylation, the cleavage of a
N-oxide bounds, proteolysis, denitration, deconjugation, thiazole
ring opening, deglycosylation and demethylation. Haiser and
Turnbaugh recently pointed out the relevance of the bioremedia-
tion literature; particularly as concerns the metabolism of
environmental chemicals:20 a catalogue of microbial biocatalytic
reactions on environmental pollutants currently lists almost 1,500
reactions carried out by 529 microorganisms affecting some 1,369
compounds.22 The GI microbiota is thought to be less diverse than
that of soil environments,23 but these ﬁndings nevertheless
suggest that the GI bacteria may have a signiﬁcant, but under-
estimated, capacity to metabolise environmental chemicals.
The GI tract is the main route by which xenobiotics enter the
human body. The rate and extent of bacterial metabolism is
inﬂuenced by the amounts of xenobiotics reaching the distal gut,
where bacteria concentration is maximal. Environmental chemi-
cals may be poorly absorbed after ingestion, subsequently being
swept to the distal small intestine and caecum by peristalsis.
Alternatively, they or their metabolites may partition from the
blood across the intestinal wall. Consequently, a number of
chemicals are directly metabolised by the GI microbiota
(Figure 1a). Environmental chemicals (or their metabolites) may
also be excreted in the bile. Most xenobiotics are non-polar and
are therefore absorbed in the GI tract and transported by the
portal blood to the liver for detoxiﬁcation. The liver generally
oxidises xenobiotics and produces glucuronic acid, sulfate or
glutathione conjugates. In most cases, conjugation reactions
facilitate excretion and conjugates are eliminated in urine.
However, conjugates can also be excreted in the bile. The factors
that determine whether a chemical is excreted into bile are not
Figure 1. Environmental chemicals and the GI microbiota interact via multiple mechanisms. (a) Environmental chemicals that are poorly
absorbed after ingestion are swept to the distal small intestine and caecum by peristalsis, and those that partition across the intestinal wall
from the blood may be directly metabolised by the GI microbiota. (b) Most xenobiotics are non-polar and therefore readily absorbed from the
GI tract, then transported by the portal blood to the liver for detoxiﬁcation. The liver tends to oxidise xenobiotics, forming conjugates with
glucuronic acid, sulfate, or glutathione that can be excreted in the bile and enter the intestine where microbiota metabolism can take place.
The GI microbiota generally deconjugates and reduces the hepatic xenobiotic metabolites, resulting in the formation of non-polar molecules
of lower molecular weight, which are readily reabsorbed. Microbiota-mediated deconjugation of metabolites previously conjugated by the
liver may regenerate the original xenobiotic or form new toxic metabolites. (c) Environmental chemicals can also interfere with the
composition of the GI microbiota, which may lead to detrimental consequences for the host. (d) Pollutants can also change the metabolic
activity of the GI microbiota, which may affect the activity of endogenous metabolites or the toxicity of other xenobiotics that depend on gut
bacteria for their metabolism.
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Figure 2. Examples of GI-bacteria-mediated transformations of environmental xenobiotics.
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fully understood, a general rule being that low-molecular-weight
compounds (o325 kDa) are poorly excreted into bile, whereas
compounds with higher molecular weight (4325) can be
signiﬁcantly excreted.24 Conjugates secreted into bile enter the
small intestine where their absorption from the GI tract is highly
variable. Those that are not absorbed move down to the large
intestine where they may be metabolised by the microbiota
(Figure 1b). The GI microbiota tends to deconjugate and reduce
hepatic xenobiotic metabolites, resulting in the formation of non-
polar molecules of lower molecular weight, which are readily
reabsorbed. The reabsorption of these non-polar molecules and
their return to the liver are referred to as ‘enterohepatic
circulation’. Enterohepatic circulation controls the storage and
reuse of endogenous substrates in the body, such as the bile
acids and steroids. However, it also delays the elimination of
environmental chemicals from the body.
In this section, we will brieﬂy present the xenobiotic-
metabolising capabilities of the GI microbiota. We will then
present some of the environmental pollutants identiﬁed as
substrates of the GI microbiota. We consider these pollutants by
chemical class and discuss the toxicological relevance of GI
microbiota-mediated metabolism for each chemical. As it is not
possible to discuss all xenobiotics in details in this review,
Supplementary Table 1 provides a more exhaustive list of
substrates derived from the interaction of the gut microbiota
with environmental pollutants. In addition, Figure 2 presents
examples of environmental xenobiotics and their gut-microbiota-
derived metabolites.
Xenobiotic-metabolising enzymes of the GI microbiota
Although various chemical reactions have been attributed to GI
microorganisms, only a few enzyme families have been identiﬁed
for GI microbial xenobiotic metabolism; mainly azoreductases,25,26
nitroreductases,27 β-glucuronidases,28 sulfatases29 and β-lyases30
(Figure 3).
A variety of environmental chemicals are metabolised by the
GI microbiota
Polycyclic aromatic hydrocarbons (PAHs). PAHs are among the
most widespread organic pollutants generated by the incomplete
combustion of carbon-containing fuels and are found in tobacco
smoke, urban-air particulates, diesel exhaust and some food
products, such as grilled and smoked meat. The toxicity of PAHs is
structure dependent; some have oestrogenic properties and some
have been classiﬁed as probable human carcinogens. Adult
exposure to PAHs has been associated with higher risks of lung
and bladder cancer.31 Van de Wiele et al. evaluated the
estrogenicity of four PAHs (naphthalene, phenanthrene, pyrene
and benzo(a)pyrene) before and after digestion by a typical
human microbiota in vitro.32 Although the parent PAH molecules
were not oestrogenic, the colonic digests displayed a signiﬁcant
oestrogenic activity. Hydroxy-PAHs, in particular 1-OH pyrene and
7-OH benzo(a)pyrene, were identiﬁed as the oestrogenic meta-
bolites. This suggests that the microorganisms present in the
human colon can bioactivate PAHs, by converting them to
oestrogenic molecules. In addition, it has been shown that rat
and human gut microbiota could regenerate benzo(a)pyrene from
Figure 3. Xenobiotic-metabolising enzymes of the GI microbiota: (i) The reductive cleavage of azo (N=N) bonds is performed by bacterial
azoreductases. Three groups of azoreductases have been described: ﬂavin-dependent NADH preferred azoreductases, ﬂavin-dependent
NADPH preferred azoreductases and ﬂavin-free NADPH preferred azoreductases. (ii) Bacterial nitroreductases reduce nitro (–NO2) functional
groups to the corresponding amines. Two types of bacterial nitroreductases have been described: type 1 nitroreductases are oxygen-
insensitive and catalyse the sequential reduction of nitro groups through the addition of electron pairs from NAD(P)H to produce the nitroso,
hydroxylamino and amino derivatives. Type 2 nitroreductases are oxygen-sensitive and catalyse the single-electron reduction of the nitro
group to produce a nitro anion radical. (iii) Endogenous sulfate esters are hydrolysed in the GI tract by sulfatases of bacterial origin.
(iv) Glutathione conjugates of xenobiotics are also extensively excreted in the bile. They are degradated by various mammalian enzymes
(γ-glutamyl transpeptidase and carboxypeptidase), resulting in the formation of cysteine conjugates. These cysteine conjugates may reach
part of the GI tract that contain ß-lyase activity and be converted to their corresponding thiol. (v) ß-glucuronidases are present throughout the
GI tract and play a role in the hydrolysis of xenobiotic glucuronides, the largest class of xenobiotic conjugates excreted in bile. The intestinal
microorganisms are thought to be the major source of ß-glucuronidase because hydrolysis of many xenobiotic glucuronides is dramatically
reduced (490%) in GF or antibiotic-treated rats.
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its hepatic conjugate, reversing the endogenous detoxiﬁcation
process, which is of potential toxicological relevance.33
Nitrated PAHs or nitro-PAHs. Nitro-PAHs are formed by the
nitration of PAHs. Humans are mainly exposed through inhalation
of nitro-PAHs present in urban-air particulate matter and diesel
fuel emissions. Nitro-PAHs display a broad spectrum of mutagenic,
genotoxic and carcinogenic properties. They are generally
extensively metabolised by the human organism with signiﬁcant
involvement of the GI microbiota.34
2-nitroﬂuorene (NF) is one of the dominant nitro-PAHs in the
environment and will be discussed further as a model compound
for nitro-PAHs. In vitro, incubation of human faeces with NF
removed the direct-acting mutagenicity of NF.35 In vivo, NF
ingested by conventional rats is reduced to 2-aminoﬂuorene
by the intestinal bacteria, acetylated and further hydroxylated
in the liver. This metabolic route is quantitatively the most
important and results in the formation of hydroxylated
2-acetylaminoﬂuorene.36 An alternative metabolic route results
in the formation of hydroxylated nitroﬂuorenes, which are
responsible for direct-acting mutagenicity.36 Comparison of NF
metabolism in GF versus conventional rats showed that, after
ingestion, the mutagenic potential of urine derived from GF
animals was 6 times higher than the one derived from
conventional animals.36 It was shown that this effect was mainly
due to the presence of hydroxylated-NF and the absence of
hydroxylated acetylaminoﬂuorene.36 Therefore, GI bacteria appear
to protect their host from the formation of mutagenic metabolites
of NF. However, when comparing the potential of NF to form DNA
adducts in mice with or without microbiota (conventional mice,
mice re-conventionalised with mice faecal suspension or mice
colonised with human faecal suspension versus GF mice), none
were observed in GF mice, whereas DNA adducts were detected in
the liver, colonic epithelium and kidney of all groups of mice
hosting a microbiota.35 DNA adduct formation is regarded as a
critical event in the development of cancer and may be used as an
in vivo biomarker of cancer risk. This GI microbiota-dependant
increase in DNA adduct formation might be related to the
nitroreduction of NF by the bacteria, since 2-acetylaminoﬂuorene
is a potent carcinogen known to promote DNA adducts.37
Nitrotoluenes. Nitrotoluenes are important intermediates in the
manufacture of dyes and plastics. 2-nitrotoluene is genotoxic, and
2,6-dinitrotoluene is hepatocarcinogenic in rats.38,39 After a single
oral dose of labelled 2,4-dinitrotoluene, conventional rats
excreted four major metabolites: 2,4-dinitrobenzoic acid and
2,4-dinitrobenzyl glucuronide, resulting from oxidation and
oxidation followed by glucuronidation of the parent compound,
respectively, and 4-N-acetyl-2-nitrobenzoic acid and 2-amino-4-
nitrobenzoic acid, as a result of nitroreduction and oxidation,
respectively. These last two metabolites were barely detectable in
GF rats, suggesting that the GI microbiota is largely responsible for
the nitroreduction of 2,4-dinitrotoluene.40 Human faecal samples
can also reduce 2,4-dinitrotoluene.41 However, the genotoxicity of
2-nitrotoluene and 2,6-dinitrotoluene is due to a product of (di)
nitrobenzyl alcohol reduction rather than from reduced metabo-
lites and the gut bacteria plays an important role in this toxicity:
both 2-nitrotoluene and 2,6-dinitrotoluene are absorbed in the
small intestine and metabolised by the liver to 2-nitrobenzyl
alcohol and 2,6-dinitrobenzyl alcohol. These compounds are
conjugated with glucuronic acid before excretion in the bile.
The GI microbiota then hydrolyses the glucuronide bound and
reduces one or both of the nitro groups. The amino derivatives are
then reabsorbed and oxidised in the liver where they covalently
bind to DNA.39
Pesticides. Pesticide is a generic term that includes herbicides,
fungicides, insecticides and antimicrobials. Thousands of different
chemicals are used as pesticides, and human exposure to these
pesticides is widespread. The most frequently used chemical
families are organochlorines, organophosphates, carbamates,
triazines and pyrethroids. Little is known about the role of the
gut microbiota on their metabolism. Yet, several chemicals have
been associated with bacterial metabolism.
Dichlorodiphenyltrichloroethane (DDT) is an organochlorine
insecticide currently banned in most developed countries.
However, DDT is highly persistent and contamination is still
widespread. DDT displays oestrogenic and antiandrogenic activity
in various tissues.42 DDT exposure has been associated with
increased risk of breast, liver and testicular cancers43 and
metabolic diseases.15 Rat and human GI faeces can metabolise
DDT to dichlorodiphenyl-dichlorophenylethane (DDD).44,45 In vivo,
DDD was detected in rats receiving DDT by stomach tube and
not in those receiving DDT intraperitoneally,44 suggesting
probable involvement of the GI microbiota in DDT metabolism.
It remains unclear whether this biotransformation corresponds to
bioactivation or detoxiﬁcation, as both DDT and DDD are probable
endocrine disruptors in humans.
Propachlor is an acetamide herbicide that has not been
manufactured since 1998. Long-term propachlor treatment-
induced tumours at single sites in rats.46 Propachlor is metabo-
lised by the rat GI microbiota following the biliary excretion of
glutathione and cysteine conjugates of the parent compound.47,48
Glutathione conjugation protects against propachlor-induced
cytotoxicity in hepatocytes,49 so the deconjugation of conjugates
by GI microbiota would be expected to increase propachlor
toxicity in vivo.
Polychlorobiphenyls. PCBs form a group of 209 highly persistent
chemicals. More than one million tons of technical PCB mixtures
have been produced worldwide since their ﬁrst commercial use in
the late 1920s. Environmental exposure to PCBs has been
associated with an increased risk of breast cancer,50 adverse
reproductive outcomes,51 delayed neurodevelopment,52 impair-
ment of the immune system53 and metabolic disruptions.42
The manufacture, processing and distribution of PCBs have thus
been prohibited in most industrialised countries since the late
1980s, but they are still being released into the environment,
through inappropriate disposal practices or leaks in electrical
equipment and hydraulic systems. Human exposure to PCBs
occurs mostly via ingestion of contaminated food, but also via
inhalation and dermal absorption. The ﬁrst step in the metabolism
of PCBs is activation by oxidation catalysed by hepatic cyto-
chromes P450, leading to the formation of an arene oxide
intermediate. Two further metabolic pathways have been
reported in mammals: hydroxylation; yielding biphenylols; and
metabolism through the mercapturic acid pathway, which
generates methyl sulfone (MeSO2) metabolites.
54 The major
metabolic route is hydroxylation generally followed by excretion.
Nevertheless, signiﬁcant amounts of MeSO2 metabolites of PCBs
accumulate in tissues: the arene oxide intermediate is conjugated
to glutathione, the glutathione conjugate is cleaved to yield a
PCB–cysteine conjugate, which can be further cleaved by a
bacterial C–S-lyase enzyme, leading to the formation of a PCB
thiol. This thiol can be methylated to a PCB methyl sulﬁde
(MeS-PCB) in the GI tract, absorbed and oxidised to the
corresponding MeSO2-PCB in the liver. The gut microbiota thus
has an important role in the formation of MeSO2-PCB.
55 When
GF and conventional rodents were injected with labelled
2,4’,5-trichlorobiphenyl, the level of radioactivity was 15 times
higher in the adipose tissue,48 lung, kidney and liver56 of
conventional animals, due to the accumulation of MeSO2-triCB.
Bacteria-mediated metabolism of PCBs to MeSO2-PCBs is
toxicologically relevant as they bind to speciﬁc proteins and
accumulate in lipophylic tissues.54 In humans, they accumulate in
the liver, lungs and adipose tissue and may be responsible for the
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chronic lung dysfunction symptoms observed in a mass
food-poisoning incident.57
Metals. Many metals, such as mercury, lead, cadmium and
arsenic are potent toxicants to living organisms. The chemical
form of a metal strongly inﬂuences its rate of absorption and
excretion and its distribution in the tissues in which it exerts its
biological effects. Studies of the interconversion of the different
forms of a metal are therefore crucial to evaluate its possible
effects on health.58
Mercury may occur as an element and as inorganic and organic
compounds, all of which have different toxicological properties.
However, organic compounds of mercury are frequently the most
toxic, with methyl mercury the principal source of organic mercury
in humans. Contamination occurs through ingestion of contami-
nated ﬁsh and other aquatic food. In vitro, the incubation of
methyl mercuric chloride with rat, mouse and human faeces,
results in the production of elemental mercury.58,59 In vivo, the
importance of bacterial demethylation for the elimination of
mercury has been conﬁrmed in studies where the suppression or
absence of the GI microbiota was associated with lower faecal
excretion of total mercury60–62 and with increased accumulation
of mercury in most tissues, including the brain, the principal site of
methyl mercury toxicity.
Arsenic is a ubiquitous environmental contaminant present in
its trivalent or pentavalent state in both organic and inorganic
compounds. Human exposure occurs primarily by consumption of
contaminated ﬁsh and crustaceans. Chronic exposure is associated
with the development of bladder, liver, kidney and lung cancers.63
The reduction of arsenic acid (iAsV) to arsenous acid (iAsIII) by rat
caecal bacteria has been reported.64 In human, iAs is sequentially
methylated and predominantly excreted as dimethylarsinic acid.
This methylation process was originally considered to be a
detoxiﬁcation process but the formation of highly reactive
methylated intermediates (monomethylarsonous acid MMAIII
and dimethylarsinous acid DMAIII) has led to reconsider
methylation as an activation process. Rodent and human gut
microbes methylate iAs to monomethlyarsonic acid (MMAV),
monomethlyarsonous acid (MMAIII) and monomethylmonothioar-
sonic acid (MMMTAV).64–66 The methylation of arsenic by GI
bacteria has long been thought to have a small contribution to the
overall methylation process in vivo, because iAsV and iAsIII are
rapidly absorbed in the small intestine. However, soil- and/or
dietary-bound arsenic may be digested differently: Van de Wiele
et al. have shown that human colonic microorganisms can
also methylate arsenic in arsenic-contaminated soils in vitro.66
However, there is still no direct evidence that the microbial
metabolism of arsenic is of toxicological signiﬁcance for the host.
Bismuth is widely used in pharmaceuticals, cosmetics, catalysis,
industrial pigments, alloys and ceramic additives. Faeces samples
from human volunteers and isolated gut segments from mice
can transform bismuth into its toxic volatile derivative trimethyl-
bismuth ex vivo during anaerobic incubation, whereas gut
segments of GF mice are unable to perform this conversion.67
Remarkably, the production rates of volatile derivatives of other
elements such as arsenic, antimony, tin and lead, were also higher,
demonstrating synergetic interactions in metalloid transformation
reactions. As volatile derivatives are usually more toxic than their
inorganic precursors, these bacteria-mediated transformations
may have a signiﬁcant impact on the host, but in vivo evidence
is warranted.
Benzene derivatives. Benzene derivatives, such as nitrobenzene,
are the starting materials for the synthesis of numerous aromatic
nitro compounds and aromatic amines. Exposure of experimental
animals to nitrobenzene induces methemoglobinemia, impacts
the nervous system, causes liver necrosis and degeneration of
the seminiferous epithelium.68 However, no methaemoglobin is
detected in GF or antibiotic-treated rats upon exposure to
nitrobenzene.69,70 Ex vivo metabolism studies with isolated caecal
content demonstrated that the GI microbiota sequentially reduced
nitrobenzene to the potentially toxic intermediates nitroso-
benzene, phenylhydroxylamine and aniline.70 Antibiotic treatment
drastically diminishes excretion of reductive metabolites, offering
protection against nitrobenzene-induced methaemoglobinaemia.70
Thus, the GI microbiota is clearly a major determinant of the
metabolism and toxicity of nitrobenzene.
To the contrary, GI bacteria seem to protect against
1,3-dinitrobenzene toxicity, which causes methaemoglobinemia
in humans and laboratory animals. The administration of a single
oral dose of 1,3-dinitrobenzene caused central nervous system
toxicity (ataxia) in GF rats but not in conventional rats, whereas
repeated oral dosing with 1,3-dinitrobenzene was required to
cause ataxia in conventional rats.71 Considerable differences in the
uptake, tissue distribution and excretion of 1,3-dinitrobenzene
were observed between GF and conventional rats71 but it cannot
be concluded whether these differences are due to direct
metabolism by GI bacteria or to physiological differences such
as variations in the absorptive properties of the gut wall that are
altered in GF animals.
Azo dyes. Azo dyes are a group of compounds containing one or
more R1-N =N-R2 bonds. At least 3,000 azo dyes are used in the
textile, paper, food, cosmetics and pharmaceutical industries. Five
azo dyes are used as food colourants: Citrus Red No. 2, Allura Red,
Tartrazine, Sunset Yellow and Orange B. These commonly used
azo dyes have no adverse cytotoxic, mutagenic or carcinogenic
effects. Other azo dyes, the Sudan dyes, are used in plastics,
printing inks, waxes, leather, fabrics and ﬂoor polish. Although
Sudan dyes are banned for food usage in most countries, they are
illegally used to maintain the colour in food products. Human
exposure to Sudan dyes and Para Red occurs through ingestion,
inhalation or skin contact. Several studies have provided
unequivocal evidence that azoreductases from the GI microbiota
catalyse cleavage of the azo bond of numerous azo dyes to
produce potentially carcinogenic aromatic amines.72 For example,
human faecal suspensions can metabolise Sudan I and II and Para
Red to aniline, 2,4-dimethylaniline, o-toluidine and 4-nitroaniline.73
In vivo, azobenzene is reduced to aniline (aminobenzene) in
conventional rats but not in GF rats.74 These bacteria-dependant
metabolites are classiﬁed as carcinogen (o-toluidine) or potential
carcinogen (aniline) for humans.
Melamine. Melamine has received intense media attention as the
cause of renal failure and death in both animals and children in
China in 2008, following its addition to pet food and infant
formula to boost apparent protein content. This renal damage is
believed to result from kidney stones formed from melamine and
uric acid, or from melamine and cyanuric acid. Zheng et al.
demonstrated that melanine toxicity was signiﬁcantly attenuated
in antibiotic-treated rats and that melamine is converted to
cyanuric acid in vitro by bacteria cultured from rat faeces. They
subsequently identiﬁed a species of Klebsiella in faeces samples
that was able to generate cyanuric acid from melamine.
Finally, rats colonised with Klebsiella terrigena display exacerbated
melamine-induced nephrotoxicity.75 The renal toxicity of
melamine is thus mediated by the GI microbiota and may depend
on the exact composition and metabolic activities of the GI
microbiota.
Artiﬁcial sweeteners. Artiﬁcial sweeteners were introduced into
the human diet more than a century ago to decrease caloric intake
and are now widely found in commonly consumed foods such as
diet soft drinks and food. The impact of artiﬁcial sweetener
consumption on health is a matter of intense debate. Some
studies have shown beneﬁts of their consumption,76 whereas
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others have suggested associations with increased risk of type 2
diabetes.77 Cyclamate is one of the most widely used artiﬁcial
sweeteners in Europe. It is metabolised into cyclohexamine, which
is thought to be responsible for the carcinogenic effect of
cyclamate,78 an effect that resulted in the banning of cyclamate in
the UK and the US, although this toxicity is still controvertial.
Interestingly, cyclamate metabolism is inducible: cyclohexamine
was detected as the main urinary metabolite of 14C-cyclamate in
rats, rabbits, guinea pigs and humans, in individuals chronically
consuming cyclamate before administration of the radiolabelled
dose.79 Evidence implicating the GI microbiota as the site of
cyclamate metabolism are numerous: cyclamate was found to be
converted to cyclohexamine in vitro by the contents of the lower
gut but not by the tissues of rats pretreated with cyclamate;80 rats
given cyclamate in drinking water for several months became
‘converters’, excreting cyclohexamine, but this ability to convert
cyclamate was lost when antibiotics were added to water.81 Many
publications have extended these observations to humans,82
providing evidence that the GI microbiota is the sole site of
cyclamate metabolism.
ENVIRONMENTAL CHEMICALS CAN AFFECT THE
COMPOSITION AND/OR THE METABOLIC ACTIVITY OF THE GI
MICROBIOTA
The composition, diversity and enzymatic capacities of the gut
microbiota are readily affected by various environmental factors,
such as the host’s lifestyle, diet and use of antibiotics.83,84 Several
environmental chemicals have also been shown to inhibit GI
bacterial growth or to induce dysbiosis in vitro and in vivo.
As discussed previously, dysbiosis of the gut microbiota has
been linked to a series of intestinal and systemic diseases.85
Interestingly, most of these disorders have also been linked to
exposure to environmental chemicals. For example, there has
been a tremendous increase in the prevalence of allergic diseases
such as asthma and food allergies in the last few decades. Recent
evidence suggests that both alterations of microbial colonisation
during the perinatal period and early-life exposure to
environmental chemicals may promote dysregulated immune
responses.86–88 It therefore seems plausible that exposure to
chemicals may affect the normal colonisation of the gut by
bacteria, with effects on host physiology later in life. Therefore,
chemical-induced perturbations of the composition of the GI
microbiota may constitute an underestimated mechanism by
which they interfere with human health (Figure 1c).
Moreover, there is a growing consensus that a healthy
microbiome might not be deﬁned as an idealised assembly of
speciﬁc microbe populations, but that the microbes community
should be able to perform a set of metabolic functions together
with its host, although this set of metabolic functions is still to be
deﬁned.85 This is of particular importance because some
xenobiotics might impact the GI microbiota physiology without
inducing dysbiosis: indeed, when fresh human faecal samples
were incubated with antibiotics or with host-targeted drugs, all
host-targeted drugs resulted in signiﬁcant alterations of microbial
gene expression, including genes involved in xenobiotic
metabolism, despite minimal short-term effects on microbial
community structure.89 Such interactions may affect the
metabolism, toxicity, and risk assessment of many environmental
compounds that become toxic upon microbiome-mediated
metabolism.
We present below the environmental chemicals that have been
shown to affect the composition of the GI microbiota and those
interfering with the metabolic activity of gut microbes. These
compounds are also described in Table 1 and in more details in
Supplementary Table 2.
Pesticides
Glyphosate is the active component of Roundup (Montsanto,
St Louis, MO, USA), the most widely used herbicide worldwide. It
has been shown that the growth of Enterococcus faecalis bacteria
isolated from cattle and horse faeces is inhibited by the lowest
concentrations of glyphosate and the herbicide formulation
tested.90 Further studies demonstrated that sensitivity to glypho-
sate is dependent on the bacterial strain. In particular, in poultry,
pathogenic bacteria such as Salmonella enteritidis, Salmonella
gallinarum, Salmonella typhimurium, Clostridium perfringens and
Clostridium botulinum are highly resistant to glyphosate, whereas
beneﬁcial bacteria such as Enterococcus faecalis, Enterococcus
faecium, Bacillus badius, Biﬁdobacterium adolescentis and Lactoba-
cillus sp. are moderately to highly susceptible.91 If it were
demonstrated that glyphosate induced similar dysbiosis in
mammals, then this would be of toxicological relevance because
it would lead to a reduction of potentially beneﬁcial bacteria in the
GI tract of the host.
Chlorpyrifos is an organophosphate insecticide commonly used
to treat fruit and vegetable crops and vineyards. The effect of
chronic exposure to chlorpyrifos has been investigated in an
in vitro simulator of the human GI tract inoculated with faeces
from healthy humans, and in vivo in rats exposed from in utero
until 60 days old.92 Exposure to chlorpyrifos induced dysbiosis of
the microbial community that was associated with proliferation of
Bacteroides sp. and decreased levels of Lactobacillus sp. and
Biﬁdobacterium sp. To the best of our knowledge, this is so far, the
only study that has investigated the effect of perinatal exposure to
low doses of environmental chemicals on GI colonisation.
Metals
In mice supplied with cadmium-containing drinking water,
a sharp decrease in the populations of all microbial species was
observed.93 Breton et al. also reported minor but speciﬁc changes
in the composition of the colonic microbiota at the family and
genus levels, following chronic treatment with cadmium and lead
in mice. Heavy metal-consuming animals had smaller numbers
of Lachnospiraceae and larger numbers of Lactobacillaceae
and Erysipelotrichaceacae than control animals.94 Exposures to
these heavy metals were subtoxic and not associated with
hepatotoxicity, changes in behaviour, organ and body weights,
food intake, stool consistency or gut motility. However, low
number of Lachnospiraceae has been previously linked to
intestinal inﬂammation and suggested as a predisposition to
colitis.95 Similarly, 4-week arsenic treatment induced a signiﬁcant
decrease in mouse faecal populations of Firmicutes, but not in
Bacteroidetes. These taxonomic changes were associated with an
alteration of the metabolic activity of the gut microbiome
as demonstrated by the variation of a number of microbial
co-metabolites, such as indole derivatives, observed in urine or
faeces of exposed animals.96
Other persistent organic pollutants
Persistent organic pollutants are highly resistant to environmental
and biological degradation and therefore persist in the environ-
ment and accumulate in the food chain. Persistent organic
pollutants are ligands of the aryl hydrocarbon receptor (AhR),
which mediates the toxic effects of these compounds. Zhang
et al.97 recently (2015) demonstrated the key role of AhR activation
in promoting the toxic effect of 2,3,7,8-tetrachlorodibenzofuran
(TCDF) on gut bacteria using AhR− /− mice fed a diet enriched with
TCDF (0.6 μg/kg per day) for 5 days. TCDF modulated the gut
microbial balance by strongly depleting segmented ﬁlamentous
bacteria in the ileum of AhR+/+ but not in AhR− /− mice. TCDF also
decreased the Firmicutes/Bacteroidetes ratio in an AhR-dependant
manner. These changes were accompanied by strong metabolic
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differences in the faeces, caecal content, liver and gut tissues
between TCDF-treated and control AhR+/+ mice, whereas TCDF
had no effect on the metabolic proﬁles of AhR− /− mice. In
particular, TCDF decreased glucose and oligosaccharide concen-
trations and increased the levels of short-chain fatty acids
(butyrate and propionate) in faeces and caecal contents,
consistent with an activation of bacterial fermentation. These
ﬁndings demonstrate that exposure to persistent organic pollu-
tants has potentially a major impact on the host-microbiota
metabolic axis, through the activation of AhR signalling. The
precise mechanism of TCDF toxicity to gut bacteria remains to be
elucidated. Moreover, this study used high doses of TCDF, so it
remains to be determined whether similar changes are observed
at environmental levels of exposure.
Artiﬁcial sweeteners
As previously discussed, cyclamate metabolism is inducible, but
the increase in sulfamase activity does not seem to be associated
with any signiﬁcant taxonomic changes.98,99 However, a slight
increase in Clostridium levels has been reported following the
chronic administration of cyclamate in rats.98 Similarly, acesulfame
potassium does not seem to possess signiﬁcant anti-bacterial nor
bacterial growth-promoting effects.100 Nevertheless, these studies
were performed using culture-based methods of bacterial
detection and it may be necessary to re-assess the impact of
cyclamate and acesulfame potassium on the gut microbial
ecosystem using modern sequencing technologies. On the
contrary, there is growing evidence that aspartame, sucralose
and saccharin induce signiﬁcant dysbiosis in animals and humans
and that this dysbiosis is responsible for deleterious metabolic
effects in the host. In rats treated with Splenda (Heartland
Consumer Products, Carmel, IN, USA) (the commercial formulation
of sucralose, containing 1.1% w/w sucralose plus maltodextrin and
glucose), faecal counts of total anaerobes increased, whereas the
numbers of biﬁdobacteria, lactobacilli, Bacteroides, clostridia and
total aerobic bacteria decreased.101 This represents a reduction in
the levels of beneﬁcial bacteria to the host. Similarly, in rats fed
low doses of aspartame in drinking water (5–7 mg/kg per day), an
increase in total bacteria and in Enterobacteriaceae and Clostridium
leptum levels was observed.102 Aspartame-consuming rats also
had higher serum propionate levels and higher fasting glucose
levels. The authors suggested that aspartame directly altered the
gut microbiota, favouring propionate production, and hypothe-
sised that the end result might be an increase in hepatic
gluconeogenesis. This hypothesis is also supported by the recent
work of Suez et al.,103 who treated mice by adding saccharin,
sucralose or aspartame (5% sweetener+95% glucose) to drinking
water and observed that artiﬁcial sweetener-consuming mice
developed glucose intolerance, whereas no such intolerance was
observed in mice drinking water or glucose alone. This artiﬁcial
sweetener-induced glucose intolerance was mediated by changes
to the commensal microbiota, with contributions from diverse
bacterial taxa, because treatment with broad spectrum antibiotics
protected animals against glucose intolerance phenotype. Using
saccharin as a prototype sweetener at a dose corresponding to the
ADI for humans (5 mg/kg per day), the authors further char-
acterised the faecal microbiota composition of saccharin-
consuming mice and demonstrated that saccharin induced strong
dysbiosis, with an increase in the number of bacteria from the
Bacteroides genus and the Clostridiales order. In stool samples from
saccharin-consuming mice, glycan-degradation pathways were
over-represented. Fermentation of glycans leads to the production
of various compounds, including short-chain fatty acids. Consis-
tent with this ﬁnding, faeces from saccharin-consuming mice had
high propionate and acetate levels. Finally, in a small intervention
study in humans, most of the volunteers (4/7) developed a
signiﬁcantly poorer glycemic response after 5–7 days of saccharin
consumption. The microbiota of these four responders changed
markedly during the intervention period and clustered differently
from the one of the three non-responders, in whom blood glucose
levels were not affected post-saccharin treatment.103 These results
suggest that human individuals feature a personalised response to
artiﬁcial sweeteners, possibly stemming from their differences in
microbiota composition and function.
Conclusions and perspectives
This review presents various mechanisms underlying bidirectional
interactions between environmental pollutants and GI microbiota.
The GI bacteria have broad enzymatic capacities and can metabolise
environmental chemicals from various chemical families, either
increasing or decreasing their toxicity to the mammalian host.
Conversely, environmental chemicals may also affect the composi-
tion and/or optimal function of the GI microbiota, with potential
effects on the health of the host. Overall, we estimate that the GI
microbiota represent a major player in the toxicity of environmental
contaminants. Nevertheless, there remain many challenges to
overcome in order to establish the level of risk associated with
environmental pollutants in interaction with gut bacteria. The
mechanisms of interaction between gut bacteria and endogenous
enzymes involved in drug detoxiﬁcation pathways must be
identiﬁed. This is necessary to evaluate the impact of GI microbiota
variations on endogenous xenobiotic metabolism and overall
susceptibility to environmental chemicals. Another challenge is to
assess the impact of long-term exposure to low-dose environmental
chemicals on the gut microbial ecosystem. To the best of our
knowledge, no study has investigated this question yet. Importantly,
the relevance of these microbiome-xenobiotics interactions on
human health needs to be assessed. This is particularly relevant to
metabolic disorders that have already been associated with
modulations of the gut microbiome. In this context, exposure to
environmental chemicals during the perinatal period and early
childhood may have a critical impact on the development of the GI
microbiota and related microbiota-dependent host physiological
functions, such as immune-system development. The consequences
of early exposure to pollutants must therefore be investigated as a
new factor potentially affecting the development of health disorders
later in life.
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